Page 41 - Read Online

Shah et al. Vessel Plus 2021;5:53 https://dx.doi.org/10.20517/2574-1209.2021.76 Page 11 of 11

(hATTR) amyloidosis with cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther 2020;34:357-70. DOI PubMed PMC
16. Businesswire. Alnylam reports positive topline results from HELIOS-A phase 3 study of vutrisiran in patients with HATTR
amyloidosis with polyneuropathy. Available from: https://www.businesswire.com/news/home/20210107005224/en/Alnylam-Reports-
Positive-Topline-Results-from-HELIOS-A-Phase-3-Study-of-Vutrisiran-in-Patients-with-hATTR-Amyloidosis-with-Polyneuropathy
[Last accessed on 24 Aug 2021].
17. Ackermann EJ, Guo S, Benson MD, et al. Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation
antisense oligonucleotides. Amyloid 2016;23:148-57. DOI PubMed
18. Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl
J Med 2018;379:22-31. DOI PubMed
19. Benson MD, Dasgupta NR, Rissing SM, Smith J, Feigenbaum H. Safety and efficacy of a TTR specific antisense oligonucleotide in
patients with transthyretin amyloid cardiomyopathy. Amyloid 2017;24:219-25. DOI PubMed
20. Maurer MS, Schwartz JH, Gundapaneni B, et al; ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin
amyloid cardiomyopathy. N Engl J Med 2018;379:1007-16. DOI PubMed
21. Nativi-Nicolau J, Van der meer P, Gundapaneni B, et al. Abstract 15528: tafamidis free acid 61 Mg in patients with transthyretin
amyloid cardiomyopathy. Circulation 2020;142:A15528. DOI
22. Ikram A, Donnelly JP, Sperry BW, Samaras C, Valent J, Hanna M. Diflunisal tolerability in transthyretin cardiac amyloidosis: a single
center's experience. Amyloid 2018;25:197-202. DOI PubMed
23. Rosenblum H, Castano A, Alvarez J, Goldsmith J, Helmke S, Maurer MS. TTR (Transthyretin) stabilizers are associated with
improved survival in patients with TTR cardiac amyloidosis. Circ Heart Fail 2018;11:e004769. DOI PubMed PMC
24. Judge DP, Heitner SB, Falk RH, et al. Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy. J
Am Coll Cardiol 2019;74:285-95. DOI PubMed
25. Sant'Anna R, Gallego P, Robinson LZ, et al. Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and
associated cellular toxicity. Nat Commun 2016;7:10787. DOI PubMed PMC
26. Richards DB, Cookson LM, Berges AC, et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl
J Med 2015;373:1106-14. DOI PubMed
27. Richards DB, Cookson LM, Barton SV, et al. Repeat doses of antibody to serum amyloid P component clear amyloid deposits in
patients with systemic amyloidosis. Sci Transl Med 2018;10:eaan3128. DOI PubMed
28. Galant NJ, Bugyei-Twum A, Rakhit R, et al. Substoichiometric inhibition of transthyretin misfolding by immune-targeting sparsely
populated misfolding intermediates: a potential diagnostic and therapeutic for TTR amyloidoses. Sci Rep 2016;6:25080. DOI PubMed
PMC
29. Wixner J, Pilebro B, Lundgren HE, Olsson M, Anan I. Effect of doxycycline and ursodeoxycholic acid on transthyretin amyloidosis.
Amyloid 2017;24:78-9. DOI PubMed
30. aus dem Siepen F, Bauer R, Aurich M, et al. Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an
observational study. Drug Des Devel Ther 2015;9:6319-25. DOI PubMed PMC
31. Cappelli F, Martone R, Taborchi G, et al. Epigallocatechin-3-gallate tolerability and impact on survival in a cohort of patients with
transthyretin-related cardiac amyloidosis. A single-center retrospective study. Intern Emerg Med 2018;13:873-80. DOI PubMed